GlassScriptPhysician profile
Margaret Slagle
NPI 1164951117
$886.91
in general payments reported to CMS, 2019-2025
22 companies · $755 in 2025
The $755 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $132 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $787 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $786.96 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $137.42 | 2025 | Enhertu, Datroway |
| Tempus Ai, INC | $116.95 | 2024 | |
| Incyte Corporation | $99.95 | 2025 | |
| Janssen Biotech, INC. | $63.29 | 2025 | Darzalex, Tecvayli, Talvey |
| Eisai INC. | $46.57 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.35 | 2025 | |
| Genzyme Corporation | $39.45 | 2025 | |
| Novartis Pharmaceuticals Corporation | $35.77 | 2025 | |
| Lilly USA, LLC | $34.01 | 2024-2025 | Jaypirca, Verzenio |
| Glaxosmithkline, LLC. | $29.10 | 2025 | Ojjaara |
| Pfizer INC. | $24.63 | 2025 | |
| Merck Sharp & Dohme LLC | $24.36 | 2025 | Welireg, Keytruda |
| Stemline Therapeutics INC. | $22.33 | 2025 | Orserdu |
| Adc Therapeutics America, INC. | $21.92 | 2025 | |
| Karyopharm Therapeutics INC. | $21.58 | 2025 | Xpovio |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Geron Corporation | $20.46 | 2025 | Rytelo |
| Sobi, INC | $20.15 | 2025 | |
| Celgene Corporation | $19.96 | 2025 | Reblozyl |
| Exelixis INC. | $19.21 | 2025 | Cabometyx |
| Abbvie INC. | $16.07 | 2025 | |
| Rigel Pharmaceuticals, INC. | $15.83 | 2025 | Rezlidhia, Gavreto, Tavalisse |
| E.R. Squibb & Sons, L.L.C. | $14.55 | 2025 | Opdivo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Slagle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.